300765 新诺威
已收盘 12-26 15:00:00
资讯
新帖
简况
12月26日新诺威跌6.77%，工银前沿医疗股票A基金重仓该股
证券之星 · 12-26 15:36
12月26日新诺威跌6.77%，工银前沿医疗股票A基金重仓该股
新诺威（300765）披露部分募投项目结项并补充流动资金公告，12月25日股价上涨1.96%
证券之星 · 12-25 22:09
新诺威（300765）披露部分募投项目结项并补充流动资金公告，12月25日股价上涨1.96%
新诺威(300765.SZ)子公司达雷妥尤单抗注射液获得药物临床试验批准
智通财经 · 12-23
新诺威(300765.SZ)子公司达雷妥尤单抗注射液获得药物临床试验批准
12月23日新诺威涨10.33%，工银前沿医疗股票A基金重仓该股
证券之星 · 12-23
12月23日新诺威涨10.33%，工银前沿医疗股票A基金重仓该股
新诺威最新公告：与共同投资设立合资公司聚焦于GLP-1靶点等相关产品
证券之星 · 12-22
新诺威最新公告：与共同投资设立合资公司聚焦于GLP-1靶点等相关产品
石药新诺威董事CAI LEI（蔡磊）因工作变动辞任
中金财经 · 12-22
石药新诺威董事CAI LEI（蔡磊）因工作变动辞任
新诺威(300765.SZ)子公司司库奇尤单抗注射液III期临床试验获得顶线分析数据
智通财经 · 12-18
新诺威(300765.SZ)子公司司库奇尤单抗注射液III期临床试验获得顶线分析数据
新诺威：截至2025年12月10日股东数为24,341户
证券之星 · 12-15
新诺威：截至2025年12月10日股东数为24,341户
12月12日新诺威跌8.42%，工银前沿医疗股票A基金重仓该股
证券之星 · 12-12
12月12日新诺威跌8.42%，工银前沿医疗股票A基金重仓该股
新诺威(300765.SZ)向香港联交所递交H股发行上市申请并刊发申请资料
智通财经 · 12-11
新诺威(300765.SZ)向香港联交所递交H股发行上市申请并刊发申请资料
新股消息 | 石药创新(300765.SZ)递表港交所 为全球最大化学合成咖啡因生产商
智通财经 · 12-10
新股消息 | 石药创新(300765.SZ)递表港交所 为全球最大化学合成咖啡因生产商
12月10日新诺威涨8.39%，工银前沿医疗股票A基金重仓该股
证券之星 · 12-10
12月10日新诺威涨8.39%，工银前沿医疗股票A基金重仓该股
新诺威（300765）预计2026年日常关联交易总额超6.5亿元，董事会审议通过
中金财经 · 12-09
新诺威（300765）预计2026年日常关联交易总额超6.5亿元，董事会审议通过
新诺威：截至2025年11月20日股东数为22,461户
证券之星 · 12-01
新诺威：截至2025年11月20日股东数为22,461户
集采降价影响业绩，执行董事收500万元罚单，石药集团转机何在？
投资时报 · 11-25
集采降价影响业绩，执行董事收500万元罚单，石药集团转机何在？
新诺威（300765）披露使用部分闲置募集资金进行现金管理的进展公告，11月18日股价下跌2.19%
证券之星 · 11-18
新诺威（300765）披露使用部分闲置募集资金进行现金管理的进展公告，11月18日股价下跌2.19%
新诺威（300765）1.58亿股限售股将于11月17日解禁，占总股本11.21%
证券之星 · 11-17
新诺威（300765）1.58亿股限售股将于11月17日解禁，占总股本11.21%
新诺威：157520510股限售股将于11月17日上市流通
证券日报 · 11-13
新诺威：157520510股限售股将于11月17日上市流通
新诺威涨8.57%，东吴证券二个月前给出“买入”评级
证券之星 · 11-13
新诺威涨8.57%，东吴证券二个月前给出“买入”评级
新诺威(300765.SZ)子公司帕妥珠单抗注射液上市申请获得受理
智通财经 · 11-12
新诺威(300765.SZ)子公司帕妥珠单抗注射液上市申请获得受理
加载更多
公司概况
公司名称：
石药创新制药股份有限公司
所属行业：
食品制造业
上市日期：
2019-03-22
主营业务：
石药创新制药股份有限公司的主营业务是生物制药和功能食品及原料的研发、生产和销售。公司的主要产品是ADC、mRNA疫苗以及抗体类药物、咖啡因、维生素C含片。
发行价格：
24.47
{"stockData":{"symbol":"300765","market":"SZ","secType":"STK","nameCN":"新诺威","latestPrice":36.88,"timestamp":1766732628000,"preClose":39.56,"halted":0,"volume":18946898,"delay":0,"changeRate":-0.0677,"floatShares":1405000000,"shares":1405000000,"eps":-0.0781,"marketStatus":"已收盘","change":-2.68,"latestTime":"12-26 15:00:00","open":39.38,"high":39.56,"low":36.81,"amount":711000000,"amplitude":0.0695,"askPrice":36.89,"askSize":256,"bidPrice":36.88,"bidSize":287,"shortable":0,"etf":0,"ttmEps":-0.0781,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766971800000},"marketStatusCode":5,"adr":0,"adjPreClose":39.56,"symbolType":"stock","openAndCloseTimeList":[[1766712600000,1766719800000],[1766725200000,1766732400000]],"highLimit":43.52,"lowLimit":35.6,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1404592944,"isCdr":false,"pbRate":15.07,"roa":"--","roe":"--","epsLYR":0.0384,"committee":0.461597,"marketValue":51801000000,"turnoverRate":0.0135,"status":1,"floatMarketCap":51801000000},"requestUrl":"/m/hq/s/300765","defaultTab":"news","newsList":[{"id":"2594644152","title":"12月26日新诺威跌6.77%，工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2594644152","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594644152?lang=zh_cn&edition=full","pubTime":"2025-12-26 15:36","pubTimestamp":1766734608,"startTime":"0","endTime":"0","summary":"证券之星消息，12月26日新诺威跌6.77%，收盘报36.88元，换手率1.35%，成交量18.95万手，成交额7.11亿元。重仓新诺威的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共39家，其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。该公募基金现任基金经理为赵蓓。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600016868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","300765","BK0226"],"gpt_icon":0},{"id":"2594237564","title":"新诺威（300765）披露部分募投项目结项并补充流动资金公告，12月25日股价上涨1.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594237564","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594237564?lang=zh_cn&edition=full","pubTime":"2025-12-25 22:09","pubTimestamp":1766671758,"startTime":"0","endTime":"0","summary":"截至2025年12月25日收盘，新诺威报收于39.56元，较前一交易日上涨1.96%，最新总市值为555.66亿元。该股当日开盘39.16元，最高40.41元，最低38.55元，成交额达5.03亿元，换手率为0.9%。公司近日发布公告，称已于2025年12月25日召开2025年第三次临时股东会，审议通过《关于部分募集资金投资项目结项并将节余募集资金永久补充流动资金及注销募集资金专户的议案》。公告显示，会议由董事会召集，董事长主持，出席股东代表股份占总表决权股份的84.1734%，表决程序合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122500035880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"gpt_icon":0},{"id":"2593249354","title":"新诺威(300765.SZ)子公司达雷妥尤单抗注射液获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2593249354","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593249354?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:57","pubTimestamp":1766480266,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新诺威(300765.SZ)发布公告，公司的控股子公司石药集团巨石生物制药有限公司(以下简称“巨石生物”)于近日收到国家药品监督管理局核准签发的关于达雷妥尤单抗注射液的《药物临床试验批准通知书》，将于近期开展临床试验。达雷妥尤单抗注射液是一种靶向ADP-核糖基环化酶(CD38)的重组全人源IgG1单克隆抗体，为原研药兆珂®的生物类似药，按照治疗用生物制品3.3类申报，适用于治疗多发性骨髓瘤成年患者。该产品研发遵循生物类似药相关研究指导原则，药学及非临床研究结果显示，该产品与原研参照药在质量、安全性和有效性方面高度相似，支持开展后续临床研究。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384919.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"新诺威(300765.SZ)子公司达雷妥尤单抗注射液获得药物临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300765","BK0226"],"gpt_icon":0},{"id":"2593146755","title":"12月23日新诺威涨10.33%，工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2593146755","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593146755?lang=zh_cn&edition=full","pubTime":"2025-12-23 15:37","pubTimestamp":1766475468,"startTime":"0","endTime":"0","summary":"证券之星消息，12月23日新诺威涨10.33%，收盘报39.3元，换手率2.63%，成交量36.87万手，成交额14.47亿元。重仓新诺威的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共39家，其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。该公募基金现任基金经理为赵蓓。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300019497.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226","159891"],"gpt_icon":0},{"id":"2593504485","title":"新诺威最新公告：与共同投资设立合资公司聚焦于GLP-1靶点等相关产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2593504485","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593504485?lang=zh_cn&edition=full","pubTime":"2025-12-22 17:43","pubTimestamp":1766396631,"startTime":"0","endTime":"0","summary":"新诺威(300765.SZ)公告称，公司拟与中奇制药共同出资4.5亿元设立合资公司，其中公司拟以自有资金出资1.58亿元，占合资公司注册资本的35%。合资公司拟主营创新型代谢类药物的研发、产业化和商业化，主要聚焦于GLP-1靶点等相关产品，涵盖超重/肥胖和2型糖尿病等治疗领域，并不断进行新型药剂开发和适应症扩展。合资公司设立后将承接石药集团有限公司旗下全部GLP-1靶点等相关产品管线。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200021982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"gpt_icon":0},{"id":"2593100129","title":"石药新诺威董事CAI LEI（蔡磊）因工作变动辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=2593100129","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593100129?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:27","pubTimestamp":1766392022,"startTime":"0","endTime":"0","summary":"中访网数据 石药创新制药股份有限公司于2025年12月22日发布公告，公司董事会收到董事CAI LEI(蔡磊)先生的书面辞职报告。CAI LEI(蔡磊)先生因工作变动原因，申请辞去公司董事职务，辞任后不再担任公司任何职务。其辞职报告自送达董事会之日起生效。公告显示，CAI LEI(蔡磊)先生原定任期至2026年4月6日届满，此次辞任未导致公司董事会成员低于法定最低人数，不会影响公司董事会的正常运作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251222/31881169.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU0314109678.HKD","LU0072913022.USD","LU1152091168.USD","IE0008369823.USD","LU1328277881.USD","LU1807302812.USD","300765","IE00B5MMRT66.SGD","LU1152091754.HKD","LU2039709279.SGD","01093","IE00BZ08YT58.USD","BK1191","IE00BZ08YS42.EUR","LU0315179316.USD","LU0326950275.SGD","LU1226287529.USD","LU1226288170.HKD","BK1515","HK0000165453.HKD","LU0140636845.USD","BK1521","LU0501845795.SGD","LU1960683339.HKD","LU1226288253.USD","CAI","LU1008478684.HKD","SG9999004220.SGD","LU1993786604.SGD","IE0008368742.USD","BK4139","LU0880133367.SGD","BK0226","LU1226287792.SGD","BK4104","IE00B543WZ88.USD","LU1226287875.USD","LU1813983027.USD","LU1951186391.HKD","IE00B031HY20.USD","IE00BZ08YR35.GBP","LU0067412154.USD"],"gpt_icon":0},{"id":"2592973845","title":"新诺威(300765.SZ)子公司司库奇尤单抗注射液III期临床试验获得顶线分析数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2592973845","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592973845?lang=zh_cn&edition=full","pubTime":"2025-12-18 15:45","pubTimestamp":1766043917,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新诺威 发布公告，公司的控股子公司石药集团巨石生物制药有限公司开发的司库奇尤单抗注射液于近日在III期临床试验中获得顶线分析数据。该产品是巨石生物开发的全人源IgG1单克隆抗体药物，为可善挺的生物类似药。可善挺在中国获批的适应症包括6岁及以上斑块状银屑病、银屑病关节炎、强直性脊柱炎及化脓性汗腺炎，其疗效与安全性已获得广泛认可。有关详细数据将于后续学术会议及期刊上发布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["III","300765","BK0226","BK4134"],"gpt_icon":0},{"id":"2591786614","title":"新诺威：截至2025年12月10日股东数为24,341户","url":"https://stock-news.laohu8.com/highlight/detail?id=2591786614","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591786614?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:24","pubTimestamp":1765790650,"startTime":"0","endTime":"0","summary":"证券之星消息，新诺威(300765)12月15日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止12月10号股东数多少？新诺威回复：您好，感谢您对公司的关注，截至2025年12月10日，公司合并普通账户和融资融券信用账户股东数为24,341户，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500021408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"gpt_icon":0},{"id":"2590575069","title":"12月12日新诺威跌8.42%，工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590575069","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590575069?lang=zh_cn&edition=full","pubTime":"2025-12-12 15:41","pubTimestamp":1765525306,"startTime":"0","endTime":"0","summary":"证券之星消息，12月12日新诺威跌8.42%，收盘报30.99元，换手率1.94%，成交量27.2万手，成交额8.71亿元。重仓新诺威的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共39家，其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。该公募基金现任基金经理为赵蓓。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200018795.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226","159891"],"gpt_icon":0},{"id":"2590355566","title":"新诺威(300765.SZ)向香港联交所递交H股发行上市申请并刊发申请资料","url":"https://stock-news.laohu8.com/highlight/detail?id=2590355566","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590355566?lang=zh_cn&edition=full","pubTime":"2025-12-11 11:43","pubTimestamp":1765424603,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新诺威(300765.SZ)发布公告，公司已于2025年12月10日向香港联交所递交了发行境外上市股份(H股)并在香港联交所主板挂牌上市的申请，并于同日在香港联交所网站刊登了本次发行上市的申请资料。本次发行上市事项的相关申请资料为公司按照香港证监会及香港联交所的要求编制和刊发，为草拟版本，其所载资料可能会适时作出更新及修订。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380263.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0226","300765"],"gpt_icon":0},{"id":"2590800685","title":"新股消息 | 石药创新(300765.SZ)递表港交所 为全球最大化学合成咖啡因生产商","url":"https://stock-news.laohu8.com/highlight/detail?id=2590800685","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590800685?lang=zh_cn&edition=full","pubTime":"2025-12-10 21:34","pubTimestamp":1765373692,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所12月10日披露，石药创新制药股份有限公司向港交所主板递交上市申请，中信证券为其独家保荐人。全球最大的咖啡因生产商。根据弗若斯特沙利文的资料，自2020年至2024年，按收入和出货量计，该公司始终保持着全球最大化学合成咖啡因生产商地位。财务资料收入2022年度、2023年度、2024年度及2025年截至7月31日止七个月，该公司收入分别约为28.38亿元、25.39亿元、19.81亿元、12.41亿元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380106.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000165453.HKD","IE00BZ08YT58.USD","LU1008478684.HKD","LU0315179316.USD","LU1226287792.SGD","BK0226","BK1515","SG9999004220.SGD","BK1191","IE0008368742.USD","LU0072913022.USD","300765","IE00B5MMRT66.SGD","LU1993786604.SGD","IE0008369823.USD","IE00BZ08YS42.EUR","LU1152091754.HKD","IE00B031HY20.USD","HEXmain","LU0314109678.HKD","LU1951186391.HKD","LU1226287875.USD","LU0326950275.SGD","LU0880133367.SGD","LU1226288170.HKD","LU1226287529.USD","LU1807302812.USD","IE00B543WZ88.USD","LU1960683339.HKD","LU2039709279.SGD","LU1328277881.USD","LU0501845795.SGD","LU1152091168.USD","BK1521","LU1813983027.USD","LU0140636845.USD","LU0067412154.USD","LU1226288253.USD","IE00BZ08YR35.GBP","01093"],"gpt_icon":0},{"id":"2590309011","title":"12月10日新诺威涨8.39%，工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590309011","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590309011?lang=zh_cn&edition=full","pubTime":"2025-12-10 15:34","pubTimestamp":1765352092,"startTime":"0","endTime":"0","summary":"证券之星消息，12月10日新诺威涨8.39%，收盘报34.1元，换手率1.81%，成交量25.48万手，成交额8.56亿元。重仓新诺威的前十大公募基金请见下表：该股最近90天内共有1家机构给出评级，买入评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共39家，其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。该公募基金现任基金经理为赵蓓。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000019288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","300765","BK0226"],"gpt_icon":0},{"id":"2590367684","title":"新诺威（300765）预计2026年日常关联交易总额超6.5亿元，董事会审议通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2590367684","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590367684?lang=zh_cn&edition=full","pubTime":"2025-12-09 08:33","pubTimestamp":1765240381,"startTime":"0","endTime":"0","summary":"中访网数据 石药创新制药股份有限公司于2025年12月5日召开董事会，审议通过了2026年度日常关联交易预计额度议案。根据公告，公司及子公司预计2026年与关联方发生的各类日常关联交易总额上限约为65，139.89万元。其中，预计向关联方采购服务的金额最高，达25，665.00万元；预计向关联方销售商品的金额为32，277.50万元。关联交易定价将遵循市场价格原则。该议案尚需提交公司股东大会审议，关联股东需回避表决。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251209/31852176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0226","300765"],"gpt_icon":0},{"id":"2588727586","title":"新诺威：截至2025年11月20日股东数为22,461户","url":"https://stock-news.laohu8.com/highlight/detail?id=2588727586","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588727586?lang=zh_cn&edition=full","pubTime":"2025-12-01 20:36","pubTimestamp":1764592568,"startTime":"0","endTime":"0","summary":"证券之星消息，新诺威(300765)12月01日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，请问截止11.20日最新股东户数是多少？谢谢。新诺威回复：您好，感谢您对公司的关注，截至2025年11月20日，公司合并普通账户和融资融券信用账户股东数为22,461户，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100032718.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"gpt_icon":0},{"id":"2586114440","title":"集采降价影响业绩，执行董事收500万元罚单，石药集团转机何在？","url":"https://stock-news.laohu8.com/highlight/detail?id=2586114440","media":"投资时报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586114440?lang=zh_cn&edition=full","pubTime":"2025-11-25 16:07","pubTimestamp":1764058020,"startTime":"0","endTime":"0","summary":"今年前三季度，石药集团收入与溢利双降。券商研报认为，公司研发投入加大可能拖累利润率今年前三季度，石药集团（01093.HK）成药业务依然承压。期内，公司实现收入198.91亿元，同比下滑12.3 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251125/c672719224.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["300765","BK0226"],"gpt_icon":0},{"id":"2584933060","title":"新诺威（300765）披露使用部分闲置募集资金进行现金管理的进展公告，11月18日股价下跌2.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584933060","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584933060?lang=zh_cn&edition=full","pubTime":"2025-11-18 18:04","pubTimestamp":1763460273,"startTime":"0","endTime":"0","summary":"截至2025年11月18日收盘，新诺威报收于33.08元，较前一交易日下跌2.19%，最新总市值为464.64亿元。该股当日开盘33.75元，最高34.06元，最低32.98元，成交额达2.7亿元，换手率为0.58%。公司近日发布公告称，石药创新制药股份有限公司使用部分闲置募集资金进行现金管理，近期赎回一笔5,000万元的结构性存款，获得收益21.88万元。同时，公司以2,500万元闲置募集资金认购新的结构性存款，产品期限为2025年11月14日至2026年2月14日，预计年化收益率为1%/1.6%/1.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800028403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"gpt_icon":0},{"id":"2584691771","title":"新诺威（300765）1.58亿股限售股将于11月17日解禁，占总股本11.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584691771","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584691771?lang=zh_cn&edition=full","pubTime":"2025-11-17 08:02","pubTimestamp":1763337764,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，新诺威于11月17日将有1.58亿股限售股份解禁，为公司定向增发机构配售股份，占公司总股本11.21%。本次解禁后，公司已无限售股份。新诺威主营业务：功能性原料、保健食品、特医食品的研发、生产与销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111700001977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"gpt_icon":0},{"id":"2583715599","title":"新诺威：157520510股限售股将于11月17日上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2583715599","media":"证券日报 ","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583715599?lang=zh_cn&edition=full","pubTime":"2025-11-13 22:06","pubTimestamp":1763042760,"startTime":"0","endTime":"0","summary":"证券日报网讯 11月13日晚间，新诺威发布关于发行股份购买资产并募集配套资金暨关联交易之部分限售股份解除限售上市流通的提示性公告称，公司本次解除限售股东数量共计1名，解除限售股份数量为157，520，510股，占公司总股本的11.2147%。本次限售股份可上市流通日期为2025年11月17日（星期一）。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-13/doc-infxhqmr2293665.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-13/doc-infxhqmr2293665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300765","BK0226"],"gpt_icon":0},{"id":"2583525635","title":"新诺威涨8.57%，东吴证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2583525635","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583525635?lang=zh_cn&edition=full","pubTime":"2025-11-13 16:34","pubTimestamp":1763022889,"startTime":"0","endTime":"0","summary":"今日新诺威（300765）涨8.57%，收盘报34.34元。2025年8月17日，东吴证券研究员朱国广发布了对新诺威的研报《2025年 中 报 点 评：持 续 加 码 研 发，EGFRADC下半年有望启动首个海外注册临床》，该研报对新诺威给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为79.59%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为东吴证券的朱国广。新诺威（300765）个股概况：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300027769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","601555"],"gpt_icon":0},{"id":"2582172326","title":"新诺威(300765.SZ)子公司帕妥珠单抗注射液上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2582172326","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582172326?lang=zh_cn&edition=full","pubTime":"2025-11-12 16:43","pubTimestamp":1762937007,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新诺威 发布公告，公司控股子公司石药集团巨石生物制药有限公司于近日收到国家药品监督管理局核准签发的《受理通知书》，帕妥珠单抗注射液的上市申请获得受理。帕妥珠单抗注射液是一款重组人源化抗HER2单克隆抗体注射液，患者每3周需使用一次。本次申请主要是基于一项III期等效性临床试验，入组患者为早期或局部晚期HER2阳性乳腺癌患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1368274.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"新诺威(300765.SZ)子公司帕妥珠单抗注射液上市申请获得受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300765","BK0226"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766787729570,"stockEarnings":[{"period":"1week","weight":0.0631},{"period":"1month","weight":0.1149},{"period":"3month","weight":-0.2283},{"period":"6month","weight":-0.2895},{"period":"1year","weight":0.346},{"period":"ytd","weight":0.3876}],"compareEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":0.0257},{"period":"3month","weight":0.0354},{"period":"6month","weight":0.1575},{"period":"1year","weight":0.1664},{"period":"ytd","weight":0.1826}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"石药创新制药股份有限公司","boardCode":"AI0014","boardName":"食品制造业","stockholders":"24341人(较上一季度增加4.36%)","perCapita":"57704股","listingDate":"2019-03-22","address":"河北省石家庄市栾城区张举路62号","registeredCapital":"140459万元","survey":" 石药创新制药股份有限公司的主营业务是生物制药和功能食品及原料的研发、生产和销售。公司的主要产品是ADC、mRNA疫苗以及抗体类药物、咖啡因、维生素C含片。","listedPrice":24.47},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"新诺威(300765)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供新诺威(300765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"新诺威,300765,新诺威股票,新诺威股票老虎,新诺威股票老虎国际,新诺威行情,新诺威股票行情,新诺威股价,新诺威股市,新诺威股票价格,新诺威股票交易,新诺威股票购买,新诺威股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"新诺威(300765)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供新诺威(300765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}